L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes
Status:
Suspended
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
To document therapeutic gain achieved by cyclic application of L-ascorbic acid (LAA)
supplementation and depletion, while confirming safety and avoidance of clinically
significant scurvy, in chemorefractory patients with acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS).